Psoriasis Longitudinal Assessment and Registry
- Conditions
- Psoriasis
- Registration Number
- NCT00508547
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 15842
Inclusion Criteria:<br><br> - Have a diagnosis of psoriasis<br><br> - Incident or prevalent users of Tremfya or an IL-17 inhibitor (eg, secukinumab,<br> ixekizumab, brodalumab, bimekizumab) at the time of their enrollment. Incident users<br> are defined as those participants starting treatment within 30 days before or after<br> the enrollment visit and prevalent users are defined as those who are on treatment<br> greater than 30 days prior to the enrollment visit<br><br> - Ability to understand and sign an informed consent form<br><br> - Are willing to participate in regular follow-up visits<br><br>Exclusion Criteria:<br><br> - Refuse to consent or are unwilling to respond to requests for long term information<br> within the required time frame<br><br> - Are participating or have already planned to participate in a clinical trial with<br> non-marketed investigational agents or are participating in a Janssen-sponsored<br> clinical trial with marketed agents
Not provided
Study & Design
- Study Type
- Observational [Patient Registry]
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse Events and Serious Adverse Events
- Secondary Outcome Measures
Name Time Method Evaluation of disease features: Physicians global assessment of disease activity (PGA) Score;Evaluation of Disease Features: Body surface area;Evaluation of Disease Features: Psoriasis Area and Severity Index (PASI) Score;Dermatology Life Quality Index (DLQI) Score;EuroQOL quality of life assessment;Hospital Anxiety and Depression Scale (HADS) Score